Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

The epidermal growth factor receptor (EGFR) secondary kinase domain T790M non–small cell lung cancer (NSCLC) mutation enhances receptor catalytic activity and confers resistance to the reversible tyrosine kinase inhibitors gefitinib and erlotinib. Currently, irreversible inhibitors represent the pri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shimamura, Takeshi, Li, Danan, Ji, Hongbin, Haringsma, Henry J., Liniker, Elizabeth, Borgman, Christa L., Lowell, April M., Minami, Yuko, McNamara, Kate, Perera, Samanthi A., Zaghlul, Sara, Thomas, Roman K., Greulich, Heidi, Kobayashi, Susumu, Chirieac, Lucian R., Padera, Robert F., Kubo, Shigeto, Takahashi, Masaya, Tenen, Daniel G., Meyerson, Matthew, Wong, Kwok-Kin, Shapiro, Geoffrey I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272303/
https://ncbi.nlm.nih.gov/pubmed/18632637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-07-5428
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados